In separate analyses, the study included 52 783 patients with overweight or obesity and 27 282 patients with type 2 diabetes who were prescribed semaglutide, then propensity score matched them with users of non–GLP-1 receptor agonist antiobesity or glucose-lowering medications. The gene discussed is GLP1R; the disease is obesity disorder.